Donidalorsen

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Hereditary Angioedema

Drug Information

Target Indication

Hereditary Angioedema

Clinical Trial

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA1/19/2026

Dawnzera

Dawnzera is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.

Drug Science

Mechanism of action & safety profile

Developer

IONS

Ionis Pharmaceuticals, Inc.

Related Pipeline

Angelman Syndrome

Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

FAP

Amyotrophic Lateral Sclerosis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts